New personalized eye treatment could stretch injections to every 4 months
NCT ID NCT07389980
Summary
This study is testing a personalized, high-dose version of an existing eye injection (aflibercept 8mg) for people with a specific eye condition called polypoidal choroidal vasculopathy (PCV). The goal is to see if this stronger dose, given on a flexible schedule, can effectively control the disease while allowing for fewer injections over time—potentially stretching treatments to every 16 weeks or longer. Researchers will measure how well vision is preserved and monitor for any side effects over 96 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYPOIDAL CHOROIDAL VASCULOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yeungnam University Hospital
RECRUITINGDaegu, 42415, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.